Melanotan II — Composed Monograph

Class: Synthetic cyclic α-MSH analog (non-selective melanocortin MC1/MC3/MC4/MC5 receptor agonist) Last composed: 19 May 2026 Source layers: Pass 1 (Science, 2026-05-17) ⋅ Pass 2 (Community, 2026-05-17) — both saved in project

Score	Value	Tier
Science Score (primary — cosmetic tanning / melanogenesis)	10 / 100	D
Science Score (secondary — male erectile dysfunction)	15 / 100	C
Science Score (community — appetite suppression)	0 / 100	E
Community Score	91 / 100	S — among the highest-volume, longest-circulating cosmetic-peptide discussions in the catalog

Reference content. Not medical advice. Decisions about use require qualified medical supervision. Melanotan II is not approved as a finished drug in any major jurisdiction. Captured by the WADA 2026 Prohibited List Section S0 (non-approved substances) catch-all, prohibited at all times.

---

Identity Calibration

Subtype: three-molecule confusion. Reading any source on “Melanotan” requires resolving which of three structurally distinct α-MSH analogs from the same Arizona research lineage is being discussed:

• Melanotan I / afamelanotide (Scenesse). Linear tridecapeptide, [Nle⁴,D-Phe⁷]-α-MSH(1–13). EMA-approved 2014 / FDA-approved 2019 for erythropoietic protoporphyria as a subcutaneous implant. Clinuvel Pharmaceuticals (originally Epitan). Approved drug, distinct molecule, narrow rare-disease indication.
• Melanotan II (MT-II). Cyclic heptapeptide, Ac-Nle⁴-c[Asp⁵-His⁶-D-Phe⁷-Arg⁸-Trp⁹-Lys¹⁰]-NH₂, lactam bridge between Asp⁵ γ-carboxyl and Lys¹⁰ ε-amino, C-terminal amide. The molecule discussed in this monograph. Unapproved everywhere.
• Bremelanotide / PT-141 (Vyleesi). Free-acid analog of MT-II — same cyclic ring, C-terminal -OH instead of -NH₂: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH. FDA-approved 2019 for premenopausal hypoactive sexual desire disorder (Palatin Technologies). Approved drug, distinct molecule, sexual-function indication.

All three share a common 1980s Arizona-programme ancestry (Hadley, Hruby, Dorr, Levine). Two of the three obtained regulatory approval after Palatin sublicensing; MT-II itself was the one that did not, and was abandoned by the original sponsor in 2000. WebMD-tier ingredient monographs, TikTok creator scripts, and a non-trivial fraction of vendor pages treat “Melanotan” as a generic term covering all three — this is the single most consequential reading error in the literature on this molecule. Where the source claims MT-II is “basically FDA-approved” or “the same as PT-141 for libido,” the source is wrong on identity, not on framing.

---

1. Identity

Field	Value	Source
INN / USAN	None. Not an INN; no USAN. Investigational research peptide only	[Regulatory document — WHO INN lists, by absence; Academic secondary source — PubChem CID 92432]
Research codes / synonyms	MT-II, MT-2, Melanotan-II, [Nle⁴,Asp⁵,D-Phe⁷,Lys¹⁰]-α-MSH(4–10)-NH₂	[Academic secondary source — PubChem CID 92432]
CAS Registry Number	121062-08-6 (free base)	[Academic secondary source — PubChem CID 92432]
Molecular formula	C₅₀H₆₉N₁₅O₉ (free base)	[Academic secondary source — PubChem CID 92432]
Molecular weight	1024.2 g/mol (free base; commonly supplied as acetate salt)	[Academic secondary source — PubChem CID 92432; ChemSpider 83450]
Peptide sequence	Ac-Nle⁴-c[Asp⁵-His⁶-D-Phe⁷-Arg⁸-Trp⁹-Lys¹⁰]-NH₂. Cyclic heptapeptide; lactam bridge Asp⁵→Lys¹⁰; C-terminal amide	[Peer-reviewed preclinical study — Al-Obeidi 1989; Ryakhovsky 2008 PMC2587946]
Pharmacological class	Synthetic cyclic α-MSH analog; non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R, MC5R); negligible MC2R	[Academic secondary source — IUPHAR/BPS GtoPdb Melanocortin Receptors family] 🔴
Reported binding constants	Ki ~0.67 nM MC1, ~6.6 nM MC4, ~34 nM MC3, ~46 nM MC5	[Peer-reviewed preclinical study — Schiöth 1995 PMID 7774675] 🔴
Brand names	None. No approved finished-drug brand. Sold via grey-market vendors as “MT-2”, “Melanotan II”, “Ubertan”, and 2023–26 “Barbie drug” branded nasal sprays	[Regulatory document — MHRA FOI 24/274, MHRA FOI 21/1237]

---

2. History and Development

The α-MSH analog research programme that produced Melanotan II originated at the University of Arizona in the 1980s under Mac E. Hadley (Cell Biology), Victor J. Hruby (Chemistry), Robert T. Dorr (College of Pharmacy), and dermatologist Norman Levine [Peer-reviewed preclinical study — Al-Obeidi 1989] 🔴. The strategic rationale was chemoprevention of UV-induced skin cancer through stimulation of pre-emptive eumelanogenesis — a “therapeutic tan” induced without UV exposure. Two lead compounds emerged: Melanotan I (a linear tridecapeptide) and Melanotan II (a shorter cyclic lactam-bridged heptapeptide engineered for enhanced potency and metabolic stability). The foundational receptor pharmacology and human pilot work trace almost entirely to this single Arizona group — the dominant single-source-dependency feature of MT-II’s evidence base.

The first pilot Phase I human evaluation appeared in Dorr et al. 1996 in Life Sciences [Peer-reviewed human study — Dorr 1996]. During Phase I tanning studies, Levine and colleagues observed that male subjects experienced unintended spontaneous erections, yawning, and stretching — a serendipitous observation that re-routed an entire pharmacological line of inquiry into central melanocortinergic regulation of sexual function [Peer-reviewed human study — Wessells 1998 PMID 9679884; Hadley 2005 PMID 15996790].

The University of Arizona licensed the programme to Competitive Technologies. The tanning-focused asset (Melanotan I / afamelanotide) was sublicensed to Australian firm Epitan (renamed Clinuvel Pharmaceuticals in 2006), which pivoted away from cosmetic tanning toward erythropoietic protoporphyria, culminating in EMA marketing authorisation (Scenesse, 2014) and FDA approval (2019). The pro-erectile asset (Melanotan II) was separately licensed to Palatin Technologies, which discontinued MT-II development in 2000 and proceeded with the successor metabolite-like analog bremelanotide (PT-141, C-terminal free acid rather than amide), ultimately FDA-approved as Vyleesi (2019) for premenopausal HSDD [Regulatory document — FDA Vyleesi label].

Melanotan II itself was never advanced to Phase 3 by any sponsor, and no marketing authorisation for MT-II exists in any major jurisdiction. From the mid-2000s onward, MT-II proliferated as a grey-market self-injected lyophilised peptide — sold via internet vendors, gyms, beauty salons, and tanning parlours. This phenomenon prompted formal regulatory action: FDA Warning Letter to Melanocorp Inc. (30 August 2007) [Regulatory document — FDA] and subsequent criminal proceedings culminating in the 2016 permanent debarment of the company owner [Regulatory document — Federal Register 81 FR 79466]; MHRA public-warning waves beginning 17 November 2008 and repeated through 2014 and 2024 [Regulatory document — MHRA; UK Parliament Written Answer 200340]; Irish Medicines Board (2009), Norwegian Medicines Agency (2009), Swedish, Danish, and Dutch national regulators; TGA scheduling decisions at ACMS #22 (November 2017) and the final April 2018 decision treating melanotan products as prescription-only Schedule 4 medicines [Regulatory document — TGA Final Decision April 2018 §1.7], renewed 2022–2024 with explicit public warnings citing AUD $4.44m corporate / $888K individual penalty exposure.

---

3. Mechanism of Action

Demonstrated in humans

• MC1R activation → cutaneous melanogenesis. Subcutaneous MT-II in healthy volunteers produces measurable skin darkening at body sites without UV exposure, quantified by reflectance spectrometry, with onset within ~5 daily low-dose injections [Peer-reviewed human study — Dorr 1996]. Downstream pathway is the canonical Gs–cAMP–PKA–CREB–MITF axis driving tyrosinase upregulation and a shift toward eumelanin synthesis [Academic secondary source — IUPHAR/BPS GtoPdb MC1R entry].
• MC4R activation → centrally mediated erectile response. In two Arizona placebo-controlled crossover trials (n=10 men with psychogenic ED; n=10 men with organic ED), subcutaneous MT-II 0.025 mg/kg produced clinically apparent erections in 17 of 20 subjects in the absence of sexual stimulation, mean RigiScan tip rigidity >80% sustained ~41 minutes [Peer-reviewed human study — Wessells 1998 PMID 9679884; Wessells 2000 PMID 11018622; Wessells 2000 PMID 11035391] 🔴.
• Adverse-effect signature consistent with multi-receptor engagement. Nausea, facial flushing, yawning, and stretching reliably observed in Phase 1 dosing — consistent with central MC3R/MC4R activity and peripheral vasomotor effects [Peer-reviewed human study — Dorr 1996; Wessells 1998].

Proposed / preclinical

• MC4R-mediated suppression of food intake / energy expenditure modulation. ICV MT-II reduces food intake in multiple rodent obesity models (ob/ob, db/db, MC4R-haploinsufficient, DIO); effect abolished in MC4R-null mice [Peer-reviewed preclinical study — Fan 1997 PMID 9019399; MacNeil 2002 PMID 12007532]. Thermogenic responses in the medial preoptic nucleus [Monge-Roffarello 2014 PMID 24808495]. No controlled human appetite trial of MT-II has been published.
• MC3R signalling in energy homeostasis and inflammation. Mostly inferred from MC3R-knockout rodent phenotypes.
• MC5R-mediated exocrine / sebaceous gland effects. Rodent data only.
• Cardiovascular effects via paraventricular nucleus MC3R/MC4R. Sympathetic outflow and blood-pressure modulation demonstrated in rodents [Li 2013 PMID 22872662]; proposed as candidate mechanism for human reports of PRES/RCVS but not proven in humans.
• Peripheral nerve regeneration / neuroprotection. Rodent sciatic-nerve crush recovery [Catania 2003]. Preclinical only.
• Anti-atherosclerotic / vascular anti-inflammatory effects. Mouse models [Rinne 2014 PMID 24790139]. Preclinical only.
• Melanoma suppression in vivo (mouse). One 2020 in vivo report described tumour-suppressive activity — directionally opposite to the cutaneous safety signal in humans. Not replicated.

Not demonstrated / common overclaims

• “Internal SPF” / sunburn protection from cosmetic MT-II. No controlled human trial. The afamelanotide / Scenesse photoprotection indication is for a specific rare photodermatosis (erythropoietic protoporphyria) and does not generalise to cosmetic MT-II use. Mechanistically, deliberate UV co-exposure (the standard tanning protocol) plausibly raises rather than lowers melanoma risk.
• Direct telomere / longevity effects. No claim base in the peer-reviewed MT-II literature.
• GH / IGF-1 axis effects. None demonstrated; MT-II is not a GH secretagogue and the community does not generally claim this.

🔴 Receptor binding and selectivity data for MT-II in IUPHAR/BPS derive predominantly from Hruby-laboratory and Schiöth-laboratory ligand panels. The most-quoted constants (Ki ~0.67 nM MC1, ~6.6 nM MC4, ~34 nM MC3, ~46 nM MC5) originate from Schiöth 1995 [PMID 7774675] and related Arizona-collaboration papers.

---

4. Regulatory Status

4.1 Drug-regulatory status

• FDA (USA). Not approved for any indication. No NDA/BLA; treated as an unapproved new drug. Warning Letter issued 30 August 2007 to Melanocorp, Inc. (Hendersonville, TN) for illegal interstate marketing of injectable MT-II [Regulatory document — FDA Warning Letter 30 Aug 2007]. Subsequent criminal investigation; Melanocorp owner pleaded guilty to felony conspiracy (18 U.S.C. §371) and was permanently debarred by FDA order published in the Federal Register on 14 November 2016 [Regulatory document — 81 FR 79466 / Manookian Debarment Order]. Not on the FDA §503A bulks list as an approved bulk substance; the compound is therefore not lawfully usable as a starting material by 503A pharmacies or 503B outsourcing facilities. Cross-referenced from project knowledge: MT-II sits within the February 2027 PCAC subset alongside GHK-Cu, Cathelicidin LL-37, Dihexa, and PEG-MGF — vendor channels are pre-positioning supply ahead of that outcome.
• EMA (European Union). Not approved. No centralised marketing authorisation. EMA has approved the related but distinct linear analog afamelanotide (Scenesse, Clinuvel, EMA 2014) for erythropoietic protoporphyria — this approval does not extend to MT-II.
• MHRA (United Kingdom). Not licensed. MHRA public warning 17 November 2008 (“Don’t be fooled into thinking that Melanotan offers a shortcut to a safer and more even tan…”) followed by repeated communications; 100+ websites suspended in cooperation with ISPs through 2014. UK Parliamentary Written Answer (Q200340, June 2014): no Melanotan product holds a UK marketing authorisation; 22 Yellow Card ADR reports describing 93 reactions received by 12 June 2014 [Regulatory document — UK Parliament 2014]. MHRA FOI responses (FOI 21/1237, 2021; FOI 24/274, 2024) confirm continuing ADR reporting and clarify that injectables and pen products containing MT-II are regulated as medicines, while nasal-spray formulations are determined to be medicines only when sold with disease-treatment/prevention claims — a documented enforcement gap. May 2024 Trading Standards / BBC reporting on nasal tanning sprays and a 2024 MHRA / UK Health Security Agency / Durham Council investigation followed [Regulatory document — MHRA / Trading Standards 2024].
• TGA (Australia). Not on the Australian Register of Therapeutic Goods. At ACMS #22 (November 2017), the delegate considered MT-II; the final April 2018 scheduling decision and subsequent updates treat melanotan products containing MT-II as prescription-only medicines (Schedule 4 framework) that may not lawfully be supplied without a prescription, regardless of dose form [Regulatory document — TGA Final Decision April 2018 §1.7]. TGA explicit public-warning communications 2022 and renewed 2023–2024 cite that MT-II “development as a potential medicine was halted some years ago due to safety reasons” and that supply attracts penalties up to AUD $888,000 (individuals) / AUD $4.44 million (corporations) under the Therapeutic Goods Act 1989.
• Health Canada. Not approved. Health-product advisories on unauthorised tanning injectables have been issued, framed under the broader category of unauthorised injectable peptides.
• PMDA (Japan), NMPA (China), MFDS (Republic of Korea), GRLS (Russia). Not approved.
• WHO Essential Medicines List. Not listed.

4.2 Anti-doping status

• WADA 2026 Prohibited List. Not individually named on the 2026 List. Captured by Section S0 – Non-approved substances via the catch-all that captures “any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g., drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use)” [Anti-doping document — WADA 2026 Prohibited List S0]. Prohibited at all times (in-competition and out-of-competition). Non-Specified. No threshold. Therapeutic Use Exemption pathway is theoretically available but, in practice, the absence of any approved therapeutic indication makes a successful TUE extremely unlikely.
• NCAA banned drug classes. Not individually named; captured under NCAA’s “Peptide Hormones, Growth Factors, Related Substances, and Mimetics” / non-approved-substance framing analogous to S0.
• DoD / OPSS (Operation Supplement Safety). MT-II is included in OPSS guidance as an example of an illicit injectable peptide prohibited for use by service members; flagged on the OPSS dietary-supplement risk database.
• USADA Global DRO. Returns prohibited-status framing under S0 across USADA / UKAD / CCES jurisdictions (check date 2026-05-17).
• BSCG (Banned Substances Control Group). Included in the broader prohibited-peptide reference set.
• Detection window. No published validated window for MT-II in human matrices. Mass-spectrometric detection methodology has been published for forensic identification of seized product [Peer-reviewed — Breindahl 2015 LC-UV-MS/MS], not athlete biological samples. Plasma half-life is short (analogous MT-I β-phase 0.8–1.7 h by RIA, Ugwu 1997). No high-profile elite-athlete ADRV for MT-II is documented in public WADA/USADA databases as of this review date.

4.3 Last regulatory review

Last regulatory review: 2026-05-17.

---

5. Formulations and Routes

No pharmaceutical-grade, regulator-approved finished-drug formulation of Melanotan II exists in any major jurisdiction.

• Historical investigational subcutaneous injectable (Arizona Phase I/II programme, 1990s). Reconstituted from lyophilised peptide; doses in published trials ranged from ~0.01 mg/kg (Dorr 1996 pilot) to 0.025 mg/kg (Wessells erectile-dysfunction studies) administered subcutaneously. Reported as study parameters — not therapeutic recommendations.
• Grey-market subcutaneous injection (community standard). Lyophilised peptide vials (commonly 10 mg) reconstituted by end-users with bacteriostatic water and self-injected. Quality, sterility, identity, and content are unverified; vendor-stated content has been shown to diverge from analytical content in regulator-led testing [Peer-reviewed preclinical study — Breindahl 2015]. Investigational / grey-market only.
• Grey-market intranasal spray. Lower and erratic bioavailability for a cyclic heptapeptide. Frequently sold without ingredients lists. Subject of UK MHRA / Trading Standards 2024 investigations after a documented increase in adverse-effect reports. Investigational / grey-market only.
• Topical creams. Sold via some tanning-salon channels. No validated transdermal penetration demonstrated; not used in any controlled trial.
• Ophthalmic / ocular (preclinical exploratory only). Pinsuwan 1997 studied ocular absorption in rabbits as a systemic-delivery route concept; not advanced clinically.
• No oral formulation. Oral bioavailability of cyclic α-MSH analogs is negligible; in the related MT-I trial no detectable plasma drug levels followed oral dosing [Ugwu 1997 PMID 9113347].

---

6. Preclinical Evidence

• Receptor binding and selectivity. MT-II is a high-affinity, non-selective agonist of MC1R, MC3R, MC4R, and MC5R, with negligible MC2R binding. Foundational radioligand-binding constants reported in [Schiöth 1995 PMID 7774675] and the related IUPHAR/BPS entries 🔴.
• Melanogenesis models. In vitro melanocyte and in vivo frog-skin and rodent dorsal-pigment models demonstrated dose-dependent tyrosinase induction and eumelanin synthesis [Hadley & Hruby; Al-Obeidi 1989].
• Sexual function (rabbit, rodent). Systemic IV MT-II (66–133 µg/kg) increases intracavernosal pressure in anaesthetised rabbits via central melanocortin-receptor activation and downstream nitric oxide release [Van der Ploeg / Argiolas group, PMC1572913].
• Appetite / energy homeostasis. ICV MT-II suppresses feeding in ob/ob, db/db, MC4R-haploinsufficient, and DIO mouse models; effect abolished in MC4R-null mice [Fan 1997 PMID 9019399; MacNeil 2002].
• Neuroprotection. Enhanced sensory recovery after sciatic nerve crush in rats at 20 µg/kg s.c. q48h; partial protection against cisplatin neuropathy [Catania 2003].
• Vascular biology. MT-II reduces atherosclerotic plaque inflammation in apoE-/- mice [Rinne 2014 PMID 24790139].
• Tumour biology. A 2020 in vivo report described MT-II suppression of melanoma progression in a mouse model — directionally inconsistent with the human cutaneous case-report signal and not independently replicated.

---

7. Clinical Evidence

7.1 Cochrane / systematic reviews

No Cochrane systematic review specific to Melanotan II has been published as of 2026-05-17 [Cochrane Library search, by absence]. No high-quality meta-analysis of MT-II clinical trials exists, reflecting the very small primary-trial base. Narrative reviews exist [Peer-reviewed review — Habbema 2017 Int J Dermatol 56:975-980; Hadeler 2022 JAAD].

7.2 Randomized controlled trials

All published controlled human trials of Melanotan II derive from the University of Arizona group. 🔴

• Dorr et al. 1996 — Life Sciences 58(20):1777–1784. Phase I pilot, single-blind, placebo-controlled. Three healthy male volunteers. Subcutaneous MT-II ~0.01 mg/kg daily Monday–Friday × 2 consecutive weeks. Outcome: significant measurable pigmentation of face, upper body, and buttocks by reflectance spectrometry after as few as five low-dose injections. AEs: facial flushing, mild GI upset, spontaneous erections. [Peer-reviewed human study — Dorr 1996] 🔴
• Wessells et al. 1998 — J Urol 160(2):389–393, PMID 9679884. Double-blind placebo-controlled crossover. Ten men with psychogenic ED. SC MT-II 0.025 mg/kg. Outcome: clinically apparent erections in absence of sexual stimulation; significant difference vs vehicle by RigiScan. [Peer-reviewed human study — Wessells 1998] 🔴
• Wessells et al. 2000 — Urology 56(4):641–646, PMID 11018622. Double-blind placebo-controlled crossover. Ten men with organic ED risk factors (diabetes, hypertension, prior pelvic surgery). SC MT-II 0.025 mg/kg. Outcome: erectogenic activity preserved in organic ED; increased sexual desire on VAS. [Peer-reviewed human study — Wessells 2000] 🔴
• Wessells et al. 2000 (combined Arizona cohort review) — Int J Impot Res 12 Suppl 4:S74–S79, PMID 11035391. Pooled n=20. Erection in 17/20; mean RigiScan tip rigidity >80% sustained 41 min. [Peer-reviewed human study] 🔴
• Dorr / Ertl / Levine — combined-modality study of MT-II plus solar UV in healthy volunteers showing additive pigmentation. [cited by Habbema 2017]

Absence of Phase 3 / pivotal RCT. No registered, completed Phase 3 trial of MT-II for any indication exists in ClinicalTrials.gov or other ICMJE-recognised registries. No regulator has ever conducted a positive efficacy/safety review of MT-II for any therapeutic indication. The development programme was discontinued by the original sponsor in 2000 in favour of the metabolite-like successor bremelanotide / PT-141.

7.3 Observational / real-world evidence

• Habbema et al. 2017 (Int J Dermatol 56(10):975–980). Narrative review of cutaneous and systemic complications in MT-I / MT-II users.
• Hadeler et al. 2022 (JAAD). Observational analysis of online α-MSH analog vendors and product claims (35 distributors among first 100 Google hits).
• Reactions Weekly track aggregated case reports — e.g., RW 1455 (2013) summarising Kaski et al.’s PRES case.
• No prospective real-world cohort of MT-II users has been published.

7.4 Trial registry / active programs

No active registered Phase 1/2/3 trials of MT-II as of 2026-05-17 in ClinicalTrials.gov, EU Clinical Trials Information System, or ANZCTR. No eligible evidence identified in this pass.

7.5 Disputed Claims

• Melanoma causation vs eruptive-nevi association vs confounding by UV exposure. Multiple peer-reviewed case reports describe eruptive melanocytic nevi, darkening and dysplastic transformation of pre-existing nevi, and incident cutaneous melanoma temporally associated with MT-II use [Cousen 2009 PMID 19438453; Langan 2009 BMJ 338:b277 PMID 19174439; Cardones & Grichnik 2009 Arch Dermatol 145(4):441–444; Paurobally 2011; Reid 2013; Schulze 2014; Hjuler & Lorentzen 2014 Dermatology 228:34–36 PMID 24355990; Ong & Bowling 2012]. Contrasting position: Habbema 2017 review concluded that conclusive evidence for MT-II causing melanoma independent of concomitant sunbed/sun exposure is lacking. Mechanistic counter-evidence: 2020 mouse in vivo study reported MT-II suppression of melanoma progression. Resolution as of 2026-05-17: no population-level epidemiological study quantifies melanoma incidence in MT-II users; the eruptive-nevi / dysplastic-change signal is internally consistent and not seriously contested; causal melanoma risk is unresolved.
• Selection vs causation in cutaneous case reports. Virtually every published melanoma case involves concurrent solarium / sun exposure, raising the selection concern that the case-report channel captures heavy-UV-exposed individuals rather than a clean MT-II effect. Both sides published; not resolved.
• MC4R-mediated cardiovascular causation of PRES / RCVS. Kaski et al. 2013 proposed a melanocortin-system mechanism for PRES temporally linked to MT-II [Ann Intern Med 158(9):707–708]. Mechanistic plausibility supported by rodent paraventricular MC3R/MC4R sympathetic-outflow data; causation in humans not established. Field treats the report as hypothesis-generating case association.
• Bremelanotide / PT-141 ↔ Melanotan II conflation. A recurring secondary-literature error in lay and grey-market writing — see Identity Calibration and identity_warnings. Not a substantive scientific dispute; flagged here as a reading-comprehension dispute that affects every downstream claim.

---

7B. Community Evidence Layer

The community-evidence layer (Pass 2, 2026-05-17) is summarised here. Full sourcing in melanotan-ii_com_2026-05-17_C91.md. Community Score 91 / 100, Community Tier S.

Community context

MT-II entered the optimisation / cosmetic audience through a different door than most peptides in this encyclopedia. Where BPC-157 and TB-500 were originally bodybuilding-forum compounds, MT-II’s first significant grey-market footprint was in the mid-2000s cosmetic-tanning market — sold in gyms, tanning salons, and via early peptide retailers in the UK, Netherlands, and Sweden before bodybuilding forums began heavily indexing it. By ~2007 MT-II was being marketed and sold to consumers as a research chemical on dozens of online shops, primarily UK-, Netherlands-, and Sweden-based. The first significant regulator-community interaction in the consumer-facing record is the FDA Melanocorp warning (Feb 2007), followed by the UK MHRA’s November 2008 / January 2009 consumer-facing warning wave. MHRA reported shutting down 72 supply websites in a single three-month sweep — a snapshot of how dense the grey market already was.

Subcommunities that drove adoption are unusually distinct from MT-II’s peptide peers: (1) tanning / cosmetic users (the dominant volume driver, geographically skewed UK / Ireland / Netherlands / Scandinavia / Australia, historically heavily female, often non-bodybuilding); (2) bodybuilding (US + UK + global, did most of the protocol-codification work on MESO-Rx, Professional Muscle, eroids, EliteFitness, UK-Muscle); (3) gay men’s circuit / club subculture (libido and “tan-and-erection” stacking, poorly indexed Reddit + private Telegram); (4) peptide-optimisation / longevity (the smallest overlap — notably, the Huberman / Attia / Patrick / Campbell / Greenfield / Gillett / Moore tier has not produced MT-II-centric long-form content, with Derek (MPMD) the principal exception); (5) harm-reduction / dermatology-adjacent counter-community that grew rapidly post-2009 case-report wave and again after 2024 in response to the Barbie-drug TikTok phenomenon.

Current popularity trajectory (2024–2026): the “Barbie drug” wave — TikTok / Instagram resurgence beginning roughly late 2023, peaking 2024–25, in which MT-II is repackaged (often as nasal spray in pink “Barbie”-branded vials) and marketed to non-bodybuilding young women. Trade-press coverage is dense (WWD, NY Post, Yahoo Lifestyle, UNILAD, The Conversation AU, UNSW Newsroom, MDLinx, BBC, UK Sun). TikTok has banned #tanningnasalspray, #melanotan, #melanotan2; vendors and creators migrated to generic hashtags and slang “vacation peptide.”

Documented protocols

The canonical bodybuilding “loading + maintenance” protocol family — codified in the 2013 eroids.com “Dosing Protocol ~P” (reposted to Professional Muscle), reinforced by MESO-Rx multi-user threads (2008–2013), endorsed by MPMD (2019), and reproduced by ThePeptideCatalog (2026) — runs 100 mcg → 250 mcg → 500 mcg stepwise ED loading, escalate to 500 mcg ED until tan achieved, drop to 500 mcg 1–2× weekly maintenance. Premedication with Claritin/Zyrtec 10 min pre-injection blunts flush/nausea; nighttime dosing to sleep through nausea is universal. A low-dose minimum-effective variant (200 mcg EOD loading, MESO-Rx Joe lineage) is followed by already-tannable skin types. The UK / tanning-salon nasal-applicator protocol family (reconstituted 10 mg vial into saline nasal applicator, 1–3 sprays before solarium sessions) is dose-imprecise and lower-bioavailability per bodybuilding-tradition critique. The libido-only “pre-encounter” protocol (0.5–1 mg SC 30–60 min before sexual activity, MESO-Rx and r/AskGayBros) conflates routinely with PT-141. Bodybuilding stack protocol runs MT-II alongside active anabolic or GH-peptide cycles; users report compounded blood-pressure increase. The MT-1 substitution protocol (Realpeptides.co, recurrent on r/Peptides) switches users from MT-II to MT-1 when MT-II nausea/erections are intolerable.

The persistent core convention across 18+ years of named sources: reconstitute 10 mg vial with 1–2 mL bacteriostatic water, start low (100–250 mcg), inject before bed, dose in fasted state, taper to maintenance once tan established.

Claimed effects

Cosmetic skin darkening / tanning (universal); spontaneous / “easier” erections (widespread, the second-most-reported claim); libido enhancement beyond erection (widespread); appetite suppression / fat-loss adjunct (common; ThePeptideCatalog reports >50% reduction during loading; UNSW 2023 confirms “can also suppress appetite and lead to weight loss”); mole / freckle darkening (common — framed as effect AND side effect); skin “glow” beyond pigmentation (occasional, TikTok creator discourse); sun protection / “internal SPF” (occasional but contested — dermatology pushback hard); mood elevation / mild euphoria (occasional, single-source-cluster); help with sun-triggered skin conditions (occasional, conflates with afamelanotide indication); persistent “permanent” baseline darker skin (common among long-term users — MPMD multi-year n=1).

Reported side effects

Nausea on first injection (“MT2 head spin”, ≥80% of users in community estimates, ThePeptideCatalog reports peaks 2–4 h post-injection, lasts 4–6 h, bedtime dosing helps); facial flushing (widespread); yawning (one of the more diagnostic MT-II-specific signs); spontaneous / unwanted erections (common in males); priapism (occasional but headline-grabbing — community syndication of BMJ Case Reports Dreyer 2019); darkening of existing moles (widespread); new nevus / freckle appearance (“eruptive moles” — MESO-Rx multi-user, Cancer Research UK consumer page); melanoma / dysplastic-nevus anxiety (common as discourse, single-case-cluster as event); decreased appetite (framed negatively occasionally); injection-site reactions (common); increased blood pressure (common, especially on anabolic stack); rapid heart rate / chest discomfort (occasional); allergic / anaphylaxis-type reaction (BBC Edith Eagle case, single-source-cluster but high-profile); skin necrosis / abscesses at injection sites (UK Sun Chantell Tolson case, single-source-cluster); RCVS / “brain swelling” reports (occasional discourse); rhabdomyolysis (occasional discourse, Nelson 2012 case); renal infarction (single-source-cluster, Peters 2020 case); contamination / underdosing of grey-market vials (common QC anxiety pattern); “MT2 anxiety / paranoia / depersonalisation” (occasional, hard-to-classify); tanorexia / compulsive use (single-source-cluster — Yahoo Lifestyle 2025).

Community dissent

The melanoma debate is the deepest cleavage. The tanning subcommunity has, across the entire 2007–2026 arc, downplayed the melanoma signal (“Why would artificially darkening of moles be dangerous?”); the harm-reduction subcommunity (Cancer Research UK, UNSW, Conversation AU, WWD-cited dermatologists Shamban and Dubrow) treats melanoma and eruptive dysplastic nevi as the headline risk. The BJD systematic review O’Mahony 2024 documents the asymmetry empirically: “very few social media posts show Melanotan in a negative light, despite its deleterious adverse effects.” The MT-1 vs MT-2 choice is the closest MT-II has to a true within-community technical debate. The “Scenesse equivalence” misconception (“Melanotan is basically approved” / “Melanotan 1 is FDA-approved”) is heavily perpetuated by vendor pages and the WebMD ingredient monograph. The PT-141 / bremelanotide conflation has flattened MT-II’s MC4R activity into “MT-II ≡ PT-141 for libido”; ThePeptideCatalog explicitly counters this. Grey-market quality dissent is the QC-anxiety pattern familiar from BPC-157 and TB-500 Pass 2 files — Janoshik Analytical has come to play a normative role.

Stack patterns

MT-II + UV exposure is the dominant stack and effectively the default protocol family — harm-reduction commentators flag this combination as the worst-case scenario for melanoma risk. MT-II + PT-141 for libido (mechanistically redundant per the protocol-aggregator counterstance). MT-II + cardarine / clenbuterol for cutting-cycle stage tan. MT-II + finasteride is not a meaningful documented stack at named-source resolution. MT-II + tirzepatide / semaglutide (“appetite-stacking” 2024–26 emerging wave; named-source resolution thin). MT-II + GH peptides (CJC-1295 / Ipamorelin / Tesamorelin — pattern is “while you’re injecting peptides anyway, add this one”). MT-II + anabolic steroid cycle with compounded blood-pressure increase warning.

Vendor / supply context

Common 2024–2026 vendors: Peptide Sciences (10 mg vial + 3 mg × 10 multi-pack under “research use only”), Limitless Life Nootropics, Apollo Peptide Sciences, Ascension Peptides, Modern Aminos, Amino Asylum (revived after 2022–23 outage), Core Peptides, Direct Sarms, Maxim Peptides — all per the Outliyr 2026 vendor census. UK/EU tanning-channel vendors: trutan.net (named in BJD systematic review), melanotan-shop.com, melanotanexpress, Tan Junkie (positions itself as non-MT-II tanning-accelerator alternative while documenting nasal-spray practice). Pricing: 2008 baseline ~$25/vial → 2024–26 typical US peptide-vendor pricing $35–$80 per 10 mg vial; UK/EU tanning-channel nasal-spray kits retail higher per gram. QC patterns: underdosing (Tan Junkie-cited assay: 4.32–8.84 mg in 10–30 mg-labelled vials); unknown impurities (up to 6% unidentified content same study); pre-mixed nasal-spray bacterial-contamination concern. Janoshik Analytical is the dominant community third-party COA reference.

Community Score / Tier

Dimension	Score (0–25)	Reasoning
Usage volume	22	20-year community presence; thousands of forum threads across MESO-Rx, Pro Muscle, eroids, EliteFitness, UK-Muscle, Reddit (r/MelanotanII, r/Peptides, r/tanning); dozens of active 2024–26 vendors; mainstream-press coverage; TikTok / Instagram creator wave; UK tanning-salon-channel volume independent of bodybuilding
Protocol codification	23	Among the most codified peptide protocols in community circulation; 100→250→500 mcg ED loading template stable across 18+ years; intranasal vs SC route split is the principal codification fracture
Reported effect consistency	21	Users overwhelmingly agree MT-II tans, causes nausea on first injection, induces spontaneous erections in men; disagreement on side-effect severity and melanoma signal — not core effects; sun-protection claim is the most disputed
Time in circulation	25	Continuously in community conversation since approximately 2003–2007 through 2008–09 MHRA wave, 2014 priapism cluster, 2020s bodybuilding peptide revival, 2024–25 TikTok Barbie-drug wave — 20+ years
Total	91 / 100	Tier S (90–100)

Retrieval limitations

Reddit at thread-permalink resolution is the largest gap in this pass — API restrictions since mid-2023 and Pushshift deprecation make thread-level retrieval unreliable at named-source resolution. The subreddits’ existence and role are confirmed via external citation (Marie Claire / Yahoo Lifestyle explicitly route reader through Reddit; BJD systematic review aggregates social-media data); per-thread URLs and vote signals are not. No thread URLs or vote counts have been fabricated. TikTok creator videos lack permanent permalink indexing in many cases, especially for content removed under hashtag bans. Podcast episode pages retrieved (MPMD “Permanently Darken” 2019); transcripts not opened. Vendor pages opened at landing-page level for Peptide Sciences and Limitless Life Nootropics; per-product pages at the other ~11 vendors confirmed via Outliyr census without individual page opens. BBC Edith Eagle and UK Sun Chantell Tolson original reports referenced via downstream citation, not opened directly. Pre-2008 forum content partially preserved on Wayback Machine, not deep-mined. Specific Substack pieces and Twitter/X threads by named biohackers (Jay Campbell, Ben Greenfield, Dr. Tyna Moore, Kyle Gillett MD, Anabolic Doc / Dr. Thomas O’Connor) were searched for and no MT-II-specific long-form content equivalent to their BPC-157 or tirzepatide coverage was found — this absence is itself documented as a community-evidence datum.

---

8. Safety Profile

Melanotan II has an unusually rich peer-reviewed case-report literature relative to its small Phase 1/2 trial base. The lack of a regulated supply chain compounds interpretation: the toxin in a given case may be MT-II, an impurity, an unrelated peptide, or microbial contaminant from non-sterile reconstitution.

Common adverse events

Reported across Dorr 1996 and Wessells 1998/2000 [Peer-reviewed human study]: nausea / occasional vomiting (dose-dependent; troublesome at 0.025 mg/kg); facial flushing; yawning and stretching (centrally mediated melanocortin “yawning-stretching complex”); spontaneous penile erections in males; transient BP and heart-rate changes; injection-site reactions.

Serious or theoretical risks

• Generalised hyperpigmentation, often patchy/uneven; persistent darkening of areolae, axillae, palmar creases, scars, and intertriginous zones.
• Eruptive melanocytic nevi and rapid transformation of pre-existing nevi. Multiple peer-reviewed case reports [Cousen 2009 PMID 19438453; Langan 2009 PMID 19174439; Cardones 2009; Paurobally 2011; Reid 2013; Schulze 2014; Ferrándiz-Pulido 2011; Hueso-Gabriel 2012; Hadeler 2022].
• Dysplastic nevi confirmed histologically in series describing severe dysplasia among lesions excised from MT-II users [Actas Dermo-Sifiliográficas 2012].
• Melanoma cases temporally associated with MT-II use [Hjuler & Lorentzen 2014 PMID 24355990; Ong & Bowling 2012; Sivyer 2012].
• Melanonychia. Brown-to-black nail discolouration.
• Oral mucosal pigmentation [Dent J 2025 PMC12942211].
• Pyoderma gangrenosum secondary to MT-II injection [Case Rep Dermatol PMC12756945].
• Rhabdomyolysis with acute kidney injury. Nelson 2012 (Clin Toxicol 50(10):1169–1173, PMID 23121206) — 39-year-old man, 6 mg subcutaneous MT-II (mass-spectrometry confirmed identity), CK peaked at 17,773 IU/L, creatinine 2.25→1.23 mg/dL, ICU admission, sympathomimetic toxidrome.
• Renal infarction. Peters 2020 (CEN Case Reports 9(2):159–161, PMID 31953620) — proposed mechanisms thrombotic and/or direct parenchymal toxicity.
• Posterior Reversible Encephalopathy Syndrome (PRES). Kaski 2013 (Ann Intern Med 158(9):707–708; summarised in Reactions Weekly 1455).
• Reversible Cerebral Vasoconstriction Syndrome (RCVS). Discussed in Habbema 2017; mechanism candidate is melanocortin-mediated sympathetic activation.
• Ischaemic priapism. Dreyer 2019 (BMJ Case Rep 12(2):e227644 PMID 30796078) — low-flow priapism, managed with cavernosal aspiration / phenylephrine / Winter’s shunt. Mallory 2021 (Sex Med 9(1):100298 PMID 33460908) — 55-year-old man, 2 mg subcutaneous MT-II, 30-hour erection refractory to phenylephrine, required penoscrotal decompression with residual ED unresponsive to PDE5i at 15-week follow-up.
• MI / stroke in young users — sporadic case reports; signal not quantified.

Trial exclusions / special populations

The Dorr 1996 and Wessells 1998/2000 trials enrolled healthy adult males or men with defined ED phenotypes, excluding significant cardiovascular disease, prior melanoma, dysplastic-nevus syndrome, and concomitant medications affecting penile erection. Pregnancy / lactation: no human data; effectively contraindicated. Pediatric: no clinical trials; case reports of paediatric harm following inadvertent exposure exist in regulator communications but are not well indexed. Pre-existing dysplastic nevus syndrome / family history of melanoma: the case-report base concentrates risk signals in fair-skinned, high-nevus-count, sunbed-using users — the populations most likely to seek MT-II and most prone to dermatologic complications. Pre-existing cardiovascular disease / uncontrolled hypertension: the PRES, RCVS, and sympathomimetic-toxidrome signals argue caution.

Community-reported adverse signals

See Section 7B. The community-reported pattern aligns with the peer-reviewed case literature on nausea, erection / priapism, mole darkening, eruptive nevi, BP elevation, and contamination / underdosing of grey-market vials. The BBC-reported Edith Eagle anaphylaxis-type reaction and the UK Sun-reported Chantell Tolson skin-necrosis case are not peer-reviewed but are mass-circulated reference cases in 2024–25 community discourse. The “tanorexia / compulsive use” pattern is single-source-cluster but recurrent enough in 2024–25 trade press to flag.

Pharmacovigilance / regulatory safety communications

UK MHRA Yellow Card reports: 22 reports describing 93 reactions received by 12 June 2014 per UK Parliament Written Answer 200340; continuing ADR reporting confirmed in MHRA FOI 21/1237 (2021) and FOI 24/274 (2024). MHRA / Trading Standards 2024 laboratory testing found all MT-II nasal sprays tested failed labelling requirements. TGA 2023–2024 laboratory testing of seized products documented unknown ingredients, sterility concerns, and undefined dosing. OMCL Operation Resistance / Pangea 7 multinational seizure analyses identified MT-II among biopharmaceutical injectables in bulk-sized lots. Irish Medicines Board 2009 documented microbial contamination in bacteriostatic water co-supplied with melanotan powder. No retractions of the Dorr 1996, Wessells 1998/2000, Hadley/Hruby foundational pharmacology papers, or the major case reports have been identified on relevant publisher pages or via Retraction Watch as of 2026-05-17.

---

9. Drug Interactions

Published drug-interaction data for Melanotan II are sparse and largely theoretical. The science-layer record is limited:

• PDE5 inhibitors (sildenafil, tadalafil, vardenafil). Co-administration was discussed in the Arizona ED programme as mechanistically additive (central melanocortinergic initiation plus peripheral NO/cGMP amplification). Formal DDI PK studies for MT-II + PDE5i in humans have not been published.
• Sympathomimetics, MAOIs, SSRIs/SNRIs. The Nelson 2012 rhabdomyolysis/sympathomimetic case and the PRES/RCVS cases suggest theoretical additive risk with concomitant sympathomimetics. The bremelanotide (PT-141) Vyleesi label warns about administration with alcohol (orthostatic hypotension) and contraindicates use in uncontrolled hypertension / known cardiovascular disease — relevant pharmacological-class read-across rather than direct MT-II evidence.
• Antihypertensives. Theoretical interaction via MC4R-mediated sympathetic outflow; not characterised in MT-II human studies.
• Concurrent anabolic steroid or GH-peptide cycles. Bodybuilding-forum-reported compounded BP increase (MESO-Rx). Not characterised in any clinical study.
• PT-141 / bremelanotide co-administration. Mechanistically redundant rather than synergistic — both target overlapping melanocortin receptors. ThePeptideCatalog explicitly counters the community stack pattern.
• Tanning bed / solar UV exposure. Not a drug interaction per se but the dominant effect-modifier in the cutaneous-safety case literature — co-exposure is near-universal in published melanoma cases.

Drug-interaction data for MT-II are insufficient for systematic clinical guidance.

---

10. Research Gaps

• No completed Phase 3 trial of MT-II for any indication. The pivotal-evidence layer is empty.
• No long-term human safety dataset. All controlled-trial dosing windows ≤2 weeks; no prospective surveillance cohort.
• No population-level epidemiological study of melanoma incidence in MT-II users vs matched non-users. The case-report literature cannot establish causation or rule it out.
• No prospective cardiovascular safety study. The PRES/RCVS, sympathomimetic, and renal-infarction case literature is qualitative.
• Single-group dependency 🔴. Virtually all controlled human pharmacology and foundational receptor-binding panels derive from the University of Arizona / Hruby–Hadley–Dorr / Wessells collaboration; independent academic replication sparse and limited largely to confirmatory in vitro receptor pharmacology (Schiöth group).
• No regulated supply. Peptide identity, content, purity, sterility, and endotoxin status of grey-market product not assured.
• Sponsor pivot signal. Original sponsor (Palatin) and the Arizona licensee chain abandoned MT-II in favour of (a) afamelanotide for narrow dermatologic indications and (b) bremelanotide / PT-141 for sexual desire — both ultimately approved while MT-II did not. Itself a science-layer datum about development feasibility.
• No characterisation in pregnancy, lactation, paediatrics, geriatric populations.
• No validated WADA detection assay for routine athlete biological monitoring.

---

11. Bottom-Line Encyclopedia Note

Melanotan II is a non-selective synthetic cyclic α-MSH analog developed at the University of Arizona in the late 1980s as an investigational sunless-tanning agent. It has never been approved as a finished drug by any major regulator and is captured by WADA’s S0 non-approved-substances catch-all. The controlled human-efficacy evidence base consists of one Phase 1 pilot and two small Phase 2 crossover trials in men with erectile dysfunction (combined n≈23), all from a single research group, and no Phase 3 trial. The original sponsor discontinued the programme and pivoted to two structurally related but distinct molecules — afamelanotide (Scenesse, approved for erythropoietic protoporphyria) and bremelanotide (Vyleesi, approved for premenopausal HSDD). A substantial peer-reviewed case-report literature documents dermatologic (eruptive nevi, dysplastic change, melanoma associations), urological (refractory priapism), renal (rhabdomyolysis, infarction), and neurological (PRES, RCVS) adverse events in grey-market users. Grey-market supply quality is unverified. No recommendation.

---

11B. Gap Analysis - Where Science and Community Diverge

Primary pattern: High community + Low science. Community Tier S/91, Science Tier D/10 for the primary tanning claim — a 81-point gap, one of the widest in the catalog. This is the canonical community ahead of science pattern that BPC-157 anchors, with two methodological twists distinct from BPC-157.

Subclass 1: community ahead of science (tanning claim). No controlled human trial of MT-II has been powered for tanning beyond Dorr 1996’s three-subject Phase 1 pilot. No Phase 2 or 3 trial of MT-II for cosmetic tanning has been completed or registered. The 18+ year community protocol (100→250→500 mcg sub-Q ED loading, taper to 500 mcg 1–2×/week maintenance, paired with UV) is more codified than the trial dosing it putatively derives from. State as untested at scale for the indication the community uses it for.

Subclass 2: indication divergence. The molecule’s only Phase 2 evidence is for male ED (Wessells 1998/2000, n=10+10). Community uses MT-II overwhelmingly for tanning, secondarily for libido, occasionally for appetite suppression. The two-Phase-2-trial efficacy signal sits in a use-case that is not the dominant community use. Distinguish: “tested in humans for male ED” (Tier C/15) ≠ “tested in humans for cosmetic tanning” (Tier D/10, n=3 pilot only) ≠ “tested in humans for appetite suppression” (Tier E/0, preclinical only).

Subclass 3: molecule divergence (a variant of indication divergence specific to MT-II). The molecule’s actually-developed-to-approval indication exists, but in a different molecule. PT-141 / bremelanotide (FDA-approved 2019 for HSDD) is the molecule that carries the libido-related regulatory-approval value, not MT-II. Afamelanotide (Scenesse, EMA 2014 / FDA 2019 for EPP) is the molecule that carries the photoprotection-related regulatory-approval value, not MT-II. This is structurally distinct from the standard “indication divergence” pattern: it is the same Arizona programme producing three molecules, two approved and one not, with the unapproved one being the one the community uses.

Subclass 4: dose disconnect. Less dramatic than the GH/GHRH/GHS ~10× community-clinic-vs-research disconnect anchored by ipamorelin / sermorelin / tesamorelin. MT-II community doses (100–500 mcg sub-Q) sit roughly within the Dorr 1996 / Wessells 1998–2000 range (~0.01–0.025 mg/kg → ~700–2000 mcg in an 80 kg adult), though community loading doses often exceed trial doses by 2–3×. The route-disconnect is more material than the dose-disconnect: the intranasal Barbie-drug route used by 2024–25 TikTok users has lower and erratic bioavailability vs the SC route used in all Phase 1/2 trials, and the route is not equivalent — yet the dose magnitudes in community use are roughly the same numerical range regardless of route. Encoded in route_profiles.notes and evidence_flags: [dose_translation_unclear, route_dependent_evidence].

The mirror twist: where the community is right and the regulator-narrative is incomplete. The community has accurately tracked, over 18 years, three things that the regulator-narrative-of-record under-emphasises: (a) the measurable cosmetic tanning effect exists — there is no community confusion about whether MT-II actually pigments skin; Dorr 1996 confirms it at n=3; (b) the libido effect is real — Wessells 1998/2000 confirms it at n=20 combined; (c) the side-effect profile of nausea, flush, yawning, erection, BP rise is mechanistically explicable and reproducible. Where the community is wrong is on (a) the safety overhang (downplays melanoma signal that the case-report literature is internally consistent on); (b) the route equivalence (treats intranasal as equivalent to SC); (c) the molecule-identity calibration (“Melanotan = Scenesse = PT-141 = Barbie drug”); and (d) the supply-chain assumption (treats vial label as content).

Where the convergence reasserts: the community and the regulator are not in disagreement on (a) MT-II is not approved; (b) MT-II should not be sold without prescription / TGA Schedule 4 prohibits it; (c) the side effects are real and dose-related; (d) the supply chain is unverified. The disagreement is on how much weight to give the safety signal vs the cosmetic benefit — a values question, not a science question.

---

12. Three Paths

This section describes practice patterns. It is not a recommendation.

Conservative path

Define the gates that would have to be crossed before considering MT-II for cosmetic purposes: a completed Phase 3 trial of MT-II (specifically MT-II, not afamelanotide, not PT-141) for cosmetic tanning with a placebo arm, ≥1000 patient-years of follow-up; major-regulator approval based on that trial; independent replication of the safety profile (cardiovascular, dermatologic, renal) by ≥1 unaffiliated research group; published Cochrane systematic review concluding favourable benefit-risk ratio; resolution of the melanoma causation question via population-level epidemiology. None of these gates currently exists. Until they exist, the conservative path treats MT-II as off-catalog for cosmetic use and refers users seeking medical photoprotection to the approved afamelanotide (Scenesse) indication — which requires a confirmed diagnosis of erythropoietic protoporphyria and dermatologist supervision and is not a cosmetic product.

Moderate path

Treat MT-II as current Tier D/S (low science, high community), with monitoring. Practitioners working with patients who disclose existing MT-II use commonly document: (a) baseline whole-body mole mapping with dermatoscopic photography; (b) baseline blood pressure / cardiovascular review including resting ECG; (c) baseline metabolic panel including creatinine and CK; (d) personal and family history of melanoma, dysplastic nevus syndrome, fair-skinned / sunbed-using risk factors as exclusion criteria; (e) explicit documentation that patient understands the molecule is unapproved, the supply chain is unregulated, and concurrent UV exposure is the principal known risk multiplier; (f) follow-up dermatology surveillance every 6 months while active and at 12 and 24 months after cessation; (g) no co-administration with PT-141 / bremelanotide, sympathomimetics, MAOIs, or in the context of uncontrolled hypertension. Practitioners in this lane do not generally initiate MT-II — they document and surveil patients who present already using it.

High-tolerance path

The community-mitigation pattern observed in 18+ years of named-source forum practice: (a) third-party COA verification before use (Janoshik Analytical reference standard); (b) sterility / endotoxin screen on reconstituted product where vendor offers it; (c) slow titration starting 100 mcg sub-Q (not 500 mcg, the “user error vignette” on the eroids ~P guide describes a user who injected 500 mcg believing it was 50 mcg); (d) bedtime dosing to sleep through nausea; (e) Claritin/Zyrtec premedication for flush; (f) dose cap at 500 mcg ED loading / 500 mcg 1–2×/week maintenance; (g) injection-site rotation; (h) baseline bloodwork (CBC, CMP, lipid panel, hsCRP) and 4–6-week recheck; (i) baseline dermatologic mole-mapping with annual recheck minimum; (j) physician discussion if patient is on antihypertensives, anabolic cycle, or has any cardiovascular risk factor; (k) no intranasal route — SC only; (l) no stacking with PT-141; (m) explicit cessation criteria (any new mole change, any cardiovascular symptom, any priapism episode, any RCVS-suggestive headache). The 2024–25 Barbie-drug nasal-spray wave sits outside even the high-tolerance community-mitigation pattern, because it discards (a), (b), (c), (i), and (k).

---

13. Key References

Science layer

Full Pass 1 reference list in melanotan-ii_sci_2026-05-17_D10.md. Key entries:

• Foundational pharmacology. Al-Obeidi 1989; Schiöth 1995 PMID 7774675; Hadley & Hruby 1998; Hadley 2005 PMID 15996790; Hadley 2006 PMID 16426078; Ryakhovsky 2008 PMC2587946; IUPHAR/BPS Guide to PHARMACOLOGY MC family page; PubChem CID 92432; ChemSpider 83450.
• Controlled human trials. Dorr 1996 Life Sci 58(20):1777–1784; Wessells 1998 J Urol 160(2):389–393 PMID 9679884; Wessells 2000 Urology 56(4):641–646 PMID 11018622; Wessells 2000 Int J Impot Res 12 Suppl 4:S74–S79 PMID 11035391; Ugwu 1997 PMID 9113347 (MT-I PK); Lan 1994 J Pharm Sci 83:1081–1084; Pinsuwan 1997 (ocular).
• Case-report literature. Nelson 2012 PMID 23121206; Peters 2020 PMID 31953620; Dreyer 2019 PMID 30796078; Mallory 2021 PMID 33460908; Kaski 2013 Ann Intern Med 158:707–708; Cousen 2009 PMID 19438453; Langan 2009 PMID 19174439; Cardones 2009 Arch Dermatol 145:441–444; Paurobally 2011; Reid 2013; Schulze 2014; Ferrándiz-Pulido 2011; Hueso-Gabriel 2012; Ong & Bowling 2012; Hjuler & Lorentzen 2014 PMID 24355990; Case Rep Dermatol PMC12756945 (pyoderma gangrenosum); Dent J 2025 PMC12942211 (oral mucosal pigmentation); Reactions Weekly 1455:24 (2013).
• Reviews. Habbema 2017 Int J Dermatol 56(10):975–980; Hadeler 2022 JAAD; Evans-Brown 2009 BMJ 338:b566 PMID 19224885.
• Analytical / forensic. Breindahl 2015 Drug Test Anal (LC-UV-MS/MS of seized online MT-II vials).
• Mechanistic / preclinical. Fan 1997 PMID 9019399; MacNeil 2002 PMID 12007532; Li 2013 PMID 22872662; Monge-Roffarello 2014 PMID 24808495; Rinne 2014 PMID 24790139; Catania 2003.
• Regulatory documents. FDA Warning Letter Melanocorp 30 Aug 2007; Federal Register 81 FR 79466 (14 Nov 2016 Manookian Debarment Order); UK Parliament Written Answer 200340 (12 Jun 2014); MHRA FOI 21/1237; MHRA FOI 24/274; MHRA Public Statement 17 Nov 2008; TGA Final Decision April 2018 §1.7 Melanotan II; TGA blog 2024; Statens legemiddelverk warning 23 Jan 2009; HPRA / IMB warning 2009; WADA 2026 Prohibited List S0; USADA / Global DRO; DoD-OPSS.
• Comparator regulatory documents (different molecules, context only). FDA Scenesse PI 2019; EMA EPAR Scenesse 2014; FDA Vyleesi label 2019.

Community layer

Full Pass 2 reference list in melanotan-ii_com_2026-05-17_C91.md. Key entries:

• Forums. MESO-Rx (thinksteroids.com) “your experience with melanotan II” (Jul 2015), “Looking for information on Melanotan?” (Jan 2008, madhattr OP, multi-user), “Melanotan 2 dosing protocol” (thread 134424803), “Mt2 dosing”, “MT-II advice”, “Melanotan II Canadian Source and Advice”; Professional Muscle “Melanotan 2 - Best Loading and Maintenence Dosing Protocol” (thread 122010 reposted from eroids); eroids.com “Forum: Melanotan-2: Dosing Protocol ~P” (2013); legacy MelanotanForums.com.
• Biohacker write-ups / podcasts. More Plates More Dates / Derek “Will Melanotan II Permanently Darken Your Skin?” (22 May 2019, refreshed Mar 2026, article + YouTube + podcast + Twitter/X 22 May 2019, IG post Bxv_ucpnOU0); Joe Rogan Experience #2421 (Derek, MT-II not the headline topic but referenced).
• Vendor pages (commercial motive flagged). Peptide Sciences MT-II 10mg + 3mg × 10 multi-pack + MT-I 10mg + landing; Limitless Life Nootropics landing; Outliyr 2026 vendor census; Muscle and Brawn Limitless review; Peptide Protocol Wiki Limitless review; trutan.net (BJD-named); Tan Junkie “Everything You Need To Know About Nasal Tanners” (UK retailer, critical perspective); ThePeptideCatalog “Melanotan-2 Dosing: 100-250mcg Loading Protocol (2026)”; Realpeptides.co “Melanotan-1 Dosage Protocol Guide”.
• Journalism. The Conversation AU (Cairns 2025); UNSW Newsroom Jan 2023; WWD (Shamban, Dubrow, Kimberly Pratt); NY Post / Yahoo Lifestyle (BBC Edith Eagle); Yahoo Lifestyle / Marie Claire (15K-follower peptide-influencer account); UNILAD May 2025; MDLinx (UK CTSI 2024 warning; Dr Kelly Johnson-Arbor); Medium / Antonio Sandro; Cancer Research UK consumer page; Cancer Research UK Cancer News 28 Jan 2009; Cosmetics Design Europe 4 Sep 2013; Partnership for Safe Medicines; Moloney & Co Solicitors; Get Safe Online; Advanced Dermatology; Healthline.
• Community-adjacent academic. WebMD ingredient monograph (consumer-facing aggregator, reproduces naming muddle); British Journal of Dermatology BC06 systematic review (O’Mahony et al. July 2024, names trutan.net).
• TikTok / Instagram / YouTube creators. Kimberly Pratt (referenced via WWD); TikTok / @drwhitneybowe (dermatologist counter-discourse, via NY Post); Marie Claire-cited 15K-follower anonymous peptide influencer; wider TikTok creator wave under banned hashtags + “vacation peptide” slang.

Retrieval limitations

Three structural gaps materially affect this monograph and are not failures of the research method but features of the available evidence:

1. No Phase 3 trial of MT-II for any indication exists. This is not a retrieval failure — it is the state of the evidence base. The science tier (D) is the most accurate available encoding of this fact.
2. Reddit thread-permalink resolution post-2023. API restrictions and Pushshift deprecation make per-thread URLs and vote signals on r/MelanotanII, r/Peptides, r/Melanoma, r/Dermatology, r/tanning, r/AskGayBros, r/Biohackers, r/Nootropics, r/Steroids, r/PeptideUmbrella, r/longevity unreliable at named-source resolution. Subreddit existence and role confirmed via external citation; per-thread URLs and vote counts have not been fabricated.
3. The 2024–25 Barbie-drug TikTok wave is partially un-indexed. TikTok hashtag bans removed a non-trivial fraction of MT-II creator content from public indexing; trade-press secondary coverage (WWD, NY Post, Yahoo, UNILAD, The Conversation, UNSW, MDLinx, BBC, UK Sun) is the durable proxy, but per-video resolution is patchy.

---

14. Audit / Refresh Trail

• Composed date: 2026-05-19
• Pass 1 file: melanotan-ii_sci_2026-05-17_D10.md — science layer
• Pass 1 review date: 2026-05-17
• Pass 2 file: melanotan-ii_com_2026-05-17_C91.md — community layer
• Pass 2 snapshot date: 2026-05-17
• Last regulatory review: 2026-05-17 (FDA, EMA, MHRA, TGA, Health Canada, PMDA, NMPA, MFDS, GRLS, WADA, USADA Global DRO, NCAA, DoD-OPSS, BSCG)
• Last community review: 2026-05-17
• Next refresh due: 2026-11-19 (6-month interval per review.refresh_priority: high)
• Refresh triggers: FDA PCAC outcome for MT-II (February 2027 subset alongside GHK-Cu, Cathelicidin LL-37, Dihexa, PEG-MGF); MHRA / UK Trading Standards enforcement actions; new peer-reviewed case reports; new analytical-content studies on grey-market vial composition; resolution (if any) of melanoma causation question via epidemiology; Barbie-drug discourse trajectory; TikTok hashtag-enforcement evolution.
• Identity calibration status: three-molecule confusion (MT-II vs MT-I/afamelanotide vs PT-141/bremelanotide). Mirrored in identity_warnings[]. Mandatory reader-facing Identity Calibration block included.
• Calibration anchors used: TB-500 (primary — multi-molecule confusion + low-Science-Score peer); BPC-157 (secondary — single-group dependency 🔴 + community-ahead-of-science + disputed-claims-rich Section 7.5); Ipamorelin (tertiary — indication-divergence subclass). Selected by methodological pattern match per v5 anchor table, not by recency.
• Gap-matrix subclass assignment: High community + Low science, primary pattern; subclasses applied — community ahead of science (tanning); indication divergence (ED tested, tanning not Phase 2-tested, appetite preclinical only); molecule divergence (variant subclass — sister molecules approved, this one not); dose disconnect (mild) and route disconnect (material). Encoded in Section 11B prose, route_profiles.notes, evidence_flags, disputed_claims, and claim_profiles.notes per v5 transitional schema (no dose_profiles / gap_analysis schema fields yet).
• Structured fields left needs_review: true: claim_profiles[libido_sexual_effects].needs_review, claim_profiles[appetite_satiety_food_noise].needs_review (community sub-scores not separately quantified in Pass 2).

End of composed monograph.

Suggested filename: melanotan-ii_mono_2026-05-19_D10-S91.md